Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

By Cynthia Liu, Q. Zhou, Yingzhu Li, Linda V. Garner, Steve P. Watkins, L. J. Carter, Jeffrey Smoot, Anne C. Gregg, Angel Daniels, Susan R. Jervey and 1 more. ACS Central Science, 2020

1,175 citations recorded by the source corpus.

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scien...

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/bcefce5aef53be840a92db6302aff0b477daefa3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Ysrafil
2. S. Ghasemi
3. Leila Mousavizadeh
4. I. Astuti

Citations in the corpus

• Mapping the Landscape of Artificial Intelligence Applications against COVID-19 (2020, methodology): “, 2020b) , (Liu et al., 2020) and those not included in virion but that are translated in host cell and are crucial for viral replication (the nonstructural proteins, or nsp).”
• Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach (2020, neutral): “The identification of available antiviral drugs as potential candidates through drug repurposing [98,99], state of the art in silico methods to discover novel drugs [100,101], allowing the use of anti-inflammatory drugs for treating COVID-19 [102].”
• Diagnosing COVID-19: The Disease and Tools for Detection (2020, background): “11, 12 Diagnostics can play an important role in the containment of COVID-19, enabling the rapid implementation of control measures that limit the spread through case identification, isolation, and contact tracing (i.e., identifying people that may have come in contact with an infected patient).”
• Genotype and phenotype of COVID-19: Their roles in pathogenesis (2020, methodology): “There may be a biological mechanism behind this epidemiological anomaly(17).”
• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response (2020, background): “In addition to the two therapeutic approaches above, other potential therapeutic development pathways for patients with this viral infection can be done through blocking ACE2 receptors and RNA interference using siRNA or microRNA [52] [53] [54] .”